1795 Meishi Announces Board Approval for Capital Increase in South Korean Subsidiary Alvogen Korea Holdings Ltd.

Release Date: June 27, 2026
Statement Date: June 26, 2026
Statement Time: 19:45:40
Company Code: 1795
Company Name: Meishi
Subject: Announcement of Board Resolution Approving Capital Increase in South Korean Subsidiary Alvogen Korea Holdings Ltd.
Applicable Clause: Clause 20
Event Date: June 26, 2026

1. Name and Nature of the Subject (For preferred shares, specify issuance terms such as dividend rate):
Ordinary shares of Alvogen Korea Holdings Ltd., a 100%-owned South Korean subsidiary of the company.

2. Event Date: June 26, 2026 ~ June 26, 2026

3. Board Approval Date: June 26, 2026 (Minguo Year 115)

4. Other Approval Dates: Not applicable

5. Transaction Quantity, Unit Price, and Total Transaction Amount:
Number of Units: 154,779 shares
Unit Price: USD 85.57
Total Transaction Amount: USD 13,245,033.11

6. Counterparty and Relationship with the Company (If the counterparty is an individual and not a related party, name disclosure may be omitted):
Alvogen Korea Holdings Ltd. is a 100%-owned subsidiary of the company.

7. If the counterparty is a related party, state the reason for selection, previous transferor, relationships among the previous transferor, the company, and the counterparty, transfer date, and transfer amount:
Not applicable

8. If the ownership of the subject asset was held by a related party of the company within the past five years, disclose the date, price, and relationship with the company at the time of acquisition and disposal:
Not applicable

9. Matters related to the disposal of receivables (including types of collateral attached to disposed receivables; if any receivables are from related parties, disclose the party name and book value of the disposed receivables):
Not applicable

10. Gain (or loss) from disposal (not applicable for acquisition of securities) (if previously deferred, explain recognition):
Not applicable

11. Delivery or payment terms (including payment schedule and amounts), contractual restrictions, and other important agreements:
Not applicable

12. Decision-making method for the transaction, basis for price determination, and decision-making unit:
The transaction price was determined with reference to a fairness opinion issued by the accountant, and executed upon approval by the company's board of directors.

13. Net asset value per share of the securities-issuing company:
NTD 2,735.18

14. Cumulative holdings (including this transaction) of the securities involved, in terms of quantity, amount, ownership percentage, and any restrictions on rights (e.g., pledge status):
Cumulative holdings: 1,611,378 shares
Cumulative amount: NTD 5,277,342,848
Ownership percentage: 100%
Rights restrictions: None

15. Proportion of cumulative securities investments (including this transaction) under Article 3 of the 'Asset Acquisition and Disposition Rules for Publicly Issued Companies' relative to total assets and equity attributable to owners of the parent in the company’s latest financial statements, and the amount of working capital in the latest financial statements:
Percentage of total assets: 51.63%
Percentage of equity attributable to owners of the parent: 110.08%
Working capital amount: NTD 6,168,243,683

16. Broker and brokerage fees:
Not applicable

17. Specific purpose or use of the acquisition or disposal:
To enhance the efficiency of operational capital utilization

18. Dissenting directors' opinions on this transaction:
None

19. Whether this transaction is a related-party transaction: Yes

20. Date of auditor approval or audit committee consent:
June 25, 2026 (Minguo Year 115)

21. Whether the accountant issued a non-fairness opinion for this transaction: No

22. Name of accounting firm:
Yang Chi & Associates CPA Firm

23. Name of accountant:
Hu Xiang-Ning

24. Accountant’s license number:
Zhongshi CPA License No. 0191

25. Whether this involves a change in business model: No

26. Explanation of business model change:
Not applicable

27. Transaction history with the counterparty in the past year and expected in the next year:
Not applicable

28. Source of funds:
Not applicable

29. Previous material information disclosure date for the same event:
Not applicable

30. Other explanatory matters:
1. The total capital increase amount is funded by converting the company’s receivable claims against Alvogen Korea Holdings Ltd. into capital contribution.
2. The actual number of shares issued will be determined based on the conversion rate as of the capital increase benchmark date.
3. The transaction amount is calculated using the Taiwan Bank exchange rate on June 22, 2026 (1 USD = 31.64 NTD).